Smith Thomas B 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed Feb 14, 2024
Insider Transaction Report
Form 4
Smith Thomas B
EVP and Chief Medical Officer
Transactions
- Award
Common Stock
2024-02-12+30,800→ 62,980 total - Award
Common Stock
2024-02-12+4,623→ 67,603 total - Tax Payment
Common Stock
2024-02-12$33.70/sh−1,899$63,996→ 65,704 total - Tax Payment
Common Stock
2024-02-12$33.70/sh−1,300$43,810→ 64,404 total
Footnotes (5)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2025, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
- [F2]Includes 442 and 553 shares acquired on each of July 21, 2023 and January 19, 2024, respectively, under the Issuer's employee stock purchase plan.
- [F3]Effective February 12, 2024, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 4,623 performance share units ("PSUs") granted in the Issuer's prior fiscal year.
- [F4]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
- [F5]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.